Kazumasa Yamaguchi

The efficacy of MRgFUS in the treatment of uterine adenomyosis and the attendant adverse events were evaluated at 12 months postoperatively. Thirty-nine women (mean age 40.9 ± 5.0 years) with symptomatic adenomyosis who had completed their …